Clinical trial
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early…
NCT03887455 · Eisai Inc., Industry · Active, not recruiting
Key facts
| NCT number | NCT03887455 |
|---|---|
| Title | A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease |
| Official title | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease |
| Acronym | Clarity AD |
| Lead sponsor | Eisai Inc., Industry |
| Collaborators | Biogen Industry |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Early Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | Lecanemab IV, Placebo, Lecanemab SC |
| Enrollment | 1,906 |
| Start date | Mar 27, 2019 |
| Primary completion | Jun 30, 2029 |
| Completion | Jun 30, 2029 |
| First posted | Mar 25, 2019 |
| Last update posted | Oct 14, 2025 |
| Countries | Australia, Canada, China, France, Germany, Italy, Japan, Russia, Singapore, South Korea, Spain, Sweden and 2 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: